Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

New Products In Brief

This article was originally published in The Gray Sheet

Executive Summary

Debuts include Medtronic’s next-generation Arctic Front Advance for paroxysmal atrial fibrillation, Covidien’s iDrive Ultra surgical stapler and AngioDynamics’ BioFlo peripherally inserted central catheters.

You may also be interested in...



Medtronic Studies Cryoballoon As First-Line Atrial Fibrillation Option

The firm will recruit over 200 patients across 12 European sites to evaluate if its Arctic Front Advance ablation therapy can benefit as a first-line treatment for atrial fibrillation rather than drugs.

Research Briefs: First Implants Of Edwards’ Transcatheter Mitral Valve; AF Ablation Catheters Trials

Three patients have received Edwards Lifesciences’ Fortis transcatheter mitral valve. Heart Rhythm publishes results from trials of Biosense Webster’s nMARQ atrial fibrillation ablation mapping catheter and Medtronic’s Arctic Front Advance cryoballoon AF ablation catheter. More research news.

New Product Briefs: 510(k)s for bioMérieux, Navilyst Medical and Novo Nordisk

FDA clears bioMérieux’s Vitek MS system for rapid identification of disease-causing bacteria and yeast in human specimens. Navilyst Medical introduces a second BioFlo device with Endexo thrombus-resistance. More new products.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

MT031521

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel